Part 5: Using IHHT Appropriately — Why Hypoxia Is Training for Some Systems and Stress for Others

What intermittent hypoxic stimuli actually do physiologically — and why dose, baseline condition, and recovery determine the biological response

Few bioenergetic interventions have received as much attention in recent years as Intermittent Hypoxic Training (IHT) and Intermittent Hypoxic-Hyperoxic Training (IHHT).

These approaches are now being used in sports performance, preventive medicine, longevity, and, increasingly, therapeutic settings. Although IHT and IHHT are often discussed almost interchangeably, they are not identical. In conventional IHT, hypoxic intervals typically alternate with normoxic recovery periods. In IHHT, reoxygenation occurs using an increased inspired oxygen concentration.

This distinction matters scientifically. Research on intermittent hypoxia can help us understand fundamental physiological mechanisms, but it cannot automatically be extrapolated to every specific IHHT protocol.

What both approaches share, however, is fascinating:

We are not giving the body a substance whose pharmacological effect then occurs more or less directly. Instead, for a limited period of time, we alter one of the most fundamental conditions of human life — oxygen availability — and allow the organism to respond.

Hypoxic training, therefore, is not passive treatment.

It is a controlled physiological challenge.

And that is precisely where both its potential and the need for careful, individualized application begin.

Why Less Oxygen Is Information for the Body

Oxygen is anything but incidental to human physiology. Oxidative phosphorylation within the mitochondria depends on oxygen for aerobic ATP production. At the same time, the body has highly sophisticated systems for detecting and responding to changes in oxygen availability.

When oxygen availability falls, more is happening than a number changing on a pulse oximeter.

The organism recognizes that an environmental condition has changed.

Peripheral chemoreceptors — particularly the carotid bodies — respond to changes in arterial oxygen partial pressure and influence ventilation as well as cardiovascular responses. At the cellular level, oxygen-sensitive signaling pathways operate in parallel, the best known of which involve the hypoxia-inducible factors, or HIFs.

In simplified terms, HIF can be imagined as a biological weather service.

As long as oxygen availability remains stable, a particular set of metabolic and regulatory programs continues to operate. When oxygen conditions change, the molecular “weather report” changes as well, and cells begin adjusting specific programs to the new situation.

These include processes involved in erythropoiesis, vascular regulation, glucose metabolism, and other mechanisms of adaptation to hypoxia.

Experimental human research has demonstrated that intermittent hypoxia can influence HIF-dependent signaling pathways. At the same time, these findings are highly dependent on the protocol used and the population studied. They demonstrate a biological mechanism — not universal effectiveness of every form of hypoxic training for every indication.

And that distinction brings us directly to perhaps the most important point in this article.

Hypoxia Is Not a Drug — It Gives the Organism a Task

We often say that IHHT “works.”

That phrase is convenient, but biologically it can create the wrong picture. It sounds as though the intervention delivers a finished effect to the organism.

What actually happens is more interesting:

Hypoxia presents a challenge. The organism generates the response.

Think of a good teacher.

A teacher does not make a student smarter by placing the hardest possible problem in front of them. What matters is whether the problem lies slightly beyond what the student can already solve comfortably.

If the task is far too easy, there is little reason to learn.

If it is challenging but manageable, the brain has to develop new strategies.

If it lies far beyond what the student can currently handle, more difficulty does not automatically produce more learning. At some point, challenge becomes overload.

This simple logic leads directly to the principle of hormesis.

Hormesis: When the Same Challenge Can Train or Overload

Research on intermittent hypoxia has made one thing increasingly clear: there is hardly such a thing as simply “hypoxia.”

Navarrete-Opazo and Mitchell captured this particularly well in their widely cited review, describing the therapeutic potential of intermittent hypoxia as “a matter of dose.”

Depending on oxygen concentration, severity of hypoxia, duration, number of episodes, and frequency of exposure, intermittent hypoxic stimuli can produce very different physiological effects. Moderate exposure involving relatively few episodes is biologically very different from severe, high-frequency intermittent hypoxia.

This gives the concept of dose an entirely different meaning.

How low is the inspired oxygen concentration?

How long does each hypoxic interval last?

How many cycles are performed?

How far does this particular person’s oxygen saturation actually fall?

How does reoxygenation occur?

How often is the intervention repeated?

And what physiological condition is that person in before the training even begins?

All of these factors alter the biological message.

A simple image may help:

Rain is rain.

A gentle summer rain can replenish dry soil and help plants grow.

The same amount of water falling very rapidly onto already saturated soil can cause flooding.

The water itself is identical.

What changed were the dose, rate, and baseline condition of the system receiving it.

Hypoxia should be understood in much the same way.

Why Sleep Apnea and Therapeutic Hypoxia Are Not the Same Thing

Scientific precision is particularly important here.

Pathological intermittent hypoxia, such as that associated with obstructive sleep apnea, should not be equated with a controlled therapeutic hypoxia protocol. Recurrent hypoxia-reoxygenation cycles in sleep apnea can be associated with sympathetic activation, oxidative stress, and cardiovascular strain.

This research itself demonstrates why two seemingly opposite statements are equally misleading:

“Hypoxia is healthy.”

Or:

“Hypoxia is harmful.”

Both reduce a complex biological phenomenon to a label.

The relevant question is:

What kind of hypoxia? At what dose? In what temporal pattern? And in which person?

The work of Navarrete-Opazo and Mitchell illustrates this dose dependency particularly well and explicitly distinguishes low-dose intermittent hypoxia from pathological patterns of exposure.

So What Actually Happens to the Mitochondria?

In longevity and biohacking circles in particular, IHHT is frequently associated with “improving mitochondrial function.”

It is an attractive statement.

Scientifically, however, it is too broad.

Intermittent hypoxia can influence metabolic and mitochondria-related adaptive processes. What actually changes depends substantially on the protocol, training status, type of exposure, and population being studied.

We therefore need to be more precise in our language.

Mitochondrial biogenesis, respiratory capacity, substrate utilization, redox signaling, and the ability of tissue to match ATP production to ATP demand are not the same thing.

If a study demonstrates changes in one of these parameters, that does not automatically mean:

“The mitochondria now work better.”

This is where science is at its best: it forces us to look more closely.

I would therefore not make the blanket statement:

“IHHT improves mitochondria.”

A more accurate formulation is:

Under certain conditions, intermittent hypoxia can influence mitochondrial and metabolic adaptive processes. The nature and magnitude of that response depend on the protocol, training context, and individual baseline condition.

It may sound less spectacular.

But that precision is exactly what separates scientific interpretation from marketing.

And it fits the central theme of this entire series:

A method does not possess one fixed biological effect.

Biology responds to conditions.

The Device Knows the Protocol — the Body Determines the Relative Dose

This brings us to one of the most important points for clinical and practical application.

Two people can sit at the same device.

They can receive the same inspired oxygen concentration.

The program can run for exactly the same amount of time.

And yet, biologically, their bodies are not receiving the same relative stimulus.

The device setting describes the external exposure.

It does not fully describe the physiological load.

In one person, oxygen saturation may fall gradually. Heart rate and breathing remain comparatively stable, and recovery after the hypoxic interval is rapid.

In another person, the same inspired oxygen concentration may produce much faster desaturation and a more pronounced respiratory or cardiovascular response.

The device may display the same protocol.

The body is not undergoing the same training.

Imagine giving two people backpacks weighing exactly 22 pounds.

For a trained adult hiker, that may represent a manageable additional load.

For a 12-year-old child, those same 22 pounds could be extremely heavy.

Twenty-two pounds are still twenty-two pounds.

But the relative load is completely different.

That is why individualization in IHT and IHHT is not an optional luxury.

It is inherent to the biological logic of the intervention.

Acute Hypoxia Is a Real Physiological Challenge

The organism does not ignore hypoxia.

Acute oxygen reduction activates chemoreflexes and triggers respiratory and cardiovascular compensatory responses. The body attempts to maintain internal homeostasis despite altered oxygen availability.

These responses are physiological.

At the same time, they mean that the organism is being challenged.

A medically more precise way of putting this is:

Acute hypoxia represents a measurable physiological challenge to which respiratory, cardiovascular, and autonomic regulatory systems respond.

How large that challenge is relative to a particular individual again depends on their baseline condition.

Imagine a city with a well-functioning electrical grid.

On a hot summer day, thousands of households suddenly switch on their air conditioners. The grid detects the increased load and compensates. It is challenged, but it has reserve capacity.

Now imagine the same city after several substations have already failed.

The exact same additional demand now hits a very different system.

The air conditioner itself has not suddenly become dangerous.

But the available reserve within the network has changed.

This analogy is useful, but it should not be mistaken for a diagnostic rule. Fatigue, low HRV, or subjective exhaustion alone do not allow us to conclude that IHHT is inappropriate.

What we can conclude is something more nuanced:

Baseline condition, clinical context, and individual physiological response need to be part of the dosing decision.

Why a Strong Reaction Does Not Prove Good Adaptation

IHHT creates an understandable temptation:

We can see something happening.

Oxygen saturation drops.

Heart rate changes.

The patient feels the stimulus.

And all of this creates the impression:

Something is definitely happening now.

That is true.

But we still do not know what will result from it afterward.

A strong acute response initially tells us that the stimulus was physiologically relevant.

It does not prove that the dose was optimal.

The distinction is easy to understand in strength training.

If I train someone so hard that they can barely walk down the stairs for the next three days, I have unquestionably created a training stimulus.

But no serious coach would conclude from the muscle soreness alone that this must have been the smartest possible training dose.

The same principle applies to hypoxia.

The goal of good IHHT should therefore not be the most dramatic desaturation.

Not the maximum tolerable load.

And not the strongest subjective sensation.

The goal is an appropriately dosed adaptive challenge from which the organism can subsequently recover.

Which means that some of the most interesting information may only become visible once the mask has already been removed.

Some of the Most Important Information May Come After the Session

During an IHHT session, we understandably monitor parameters such as oxygen saturation and heart rate. Depending on the device and clinical setting, additional physiological information may also be available.

But if we want to understand whether the stimulus was appropriate for this particular person, observation should not end when the session does.

How does the person feel afterward?

What happens to their energy over the remainder of the day?

How do they sleep that night?

Is their normal functional capacity preserved the next morning?

Do they reliably return to their individual baseline?

Or does a relatively brief intervention create aftereffects that continue for many hours or even longer?

This does not give us a single validated IHHT metric. Rather, it follows from the general physiology of training and adaptation:

Response and recovery belong together.

Think of an IHHT session as throwing a stone into a lake.

Of course we watch the wave.

But if we want to understand the stability of the lake, we should pay just as much attention to whether and how quickly the water becomes calm again.

Why Long COVID Makes These Differences Especially Visible

Long COVID demonstrates particularly clearly why a diagnosis alone is not sufficient to determine the appropriate dose of an adaptive stimulus.

The term Long COVID encompasses very different clinical presentations. Fatigue, exercise intolerance, dyspnea, cognitive symptoms, sleep disturbances, palpitations, and orthostatic symptoms can all occur.

Alterations in autonomic regulation have also been described in subgroups. For example, Marques and colleagues found evidence of reduced cardiac autonomic modulation and greater sympathetic influence in patients with Long COVID.

But here again, we should resist turning group-level findings into a new template.

There is no single autonomic pattern of Long COVID.

And therefore there is no single HRV value that can reliably tell us whether a person should or should not receive IHHT.

Another important factor in a subset of patients is post-exertional symptom exacerbation, often referred to as PEM or PESE.

In these patients, physical, cognitive, or other forms of exertion can trigger a delayed and sometimes prolonged worsening of symptoms. Research suggests that this phenomenon occurs in a meaningful subset of people with Long COVID, although reported prevalence and severity vary considerably depending on the population studied and the way PEM is assessed.

For adaptive interventions, this distinction matters enormously.

A person who has primarily become deconditioned after an infection but still tolerates exertion and recovers from it normally is not necessarily in the same physiological situation as someone in whom even relatively minor exertion produces delayed and substantial symptom exacerbation.

Both may say:

“I’ve been exhausted since COVID.”

But that one sentence does not describe the same biological state.

Particular caution is therefore warranted with additional physiologically demanding interventions in people with pronounced PEM or an ME/CFS-like clinical presentation. Positive findings from other Long COVID populations should not automatically be extrapolated to severely affected patients with significant post-exertional symptom exacerbation.

Does That Mean IHHT Is Problematic in Long COVID?

No.

And this is where differentiation becomes especially important.

Clinical evidence now also suggests that IHHT may be well tolerated and associated with improvements in certain Long COVID settings.

Doehner and colleagues studied 145 people with Long COVID in a controlled clinical pilot trial conducted as part of an inpatient multidisciplinary rehabilitation program. The group receiving additional IHHT showed greater improvements in functional capacity and several patient-reported outcomes. IHHT was reported to be well tolerated in the population studied.

That is a very interesting signal.

But scientifically, it is equally important to ask:

What does this study not prove?

It does not prove that every person with Long COVID benefits from IHHT.

It does not prove that every IHHT protocol is appropriate.

And it does not establish that these findings can automatically be transferred to severely affected patients who are unable to participate in inpatient rehabilitation, or to people with pronounced PEM or ME/CFS-like presentations.

This was a controlled pilot study embedded within an inpatient multimodal rehabilitation program — not evidence for a universal IHHT treatment for Long COVID.

And this, to me, is where the science becomes especially interesting.

We do not need to choose between two simplistic positions:

“IHHT helps Long COVID.”

or:

“IHHT is too stressful for Long COVID.”

Both are too broad.

The better question is:

Which person, with which Long COVID phenotype, at which stage, might benefit from which form and dose of intermittent hypoxia — and which physiological and clinical responses tell us that the dose is actually appropriate?

That is more complicated.

But that is biology.

What This Means for IHHT in Practice

Once we understand hypoxia as an adaptive stimulus, our perspective on the intervention changes.

The device is no longer the center of the treatment.

And neither is the standardized protocol.

The center is the organism’s response to the protocol.

That changes the questions we ask before and during IHHT.

Not:

How low can we drive oxygen saturation?

Not:

How much hypoxia can this patient tolerate?

But:

What dose provides enough physiological challenge to stimulate adaptation in this particular person without creating a disproportionate physiological burden?

The difference between those questions may appear small.

Physiologically, it is enormous.

The first searches for a limit.

The second searches for an individual training window.

And that is where intelligent IHHT application begins.

A Deeper Look at IHHT for CFS and Long/Post-COVID

Especially in CFS or ME/CFS and Long/Post-COVID, adaptive stimuli require careful differentiation. Diagnosis, fatigue, and reduced performance alone do not tell us how a hypoxic intervention should be assessed or dosed.

For professionals and interested individuals who want to explore this subject in greater depth, the Human Change Academy offers a dedicated online course by Dr. med. Egor Egorov:

IHHT for CFS & Long COVID — Online Course by Dr. med. Egor Egorov

The course takes a closer look at the specific characteristics of this complex patient population and discusses the therapeutic use of IHHT.

Applying These Principles in Practice

I am currently working again with selected practices, clinics, and individuals in one-on-one settings and small groups to help assess regulatory states more precisely and build bioenergetic interventions around the individual system.

The objective is not to use as many methods — or as much intensity — as possible. It is to understand which stimulus may be appropriate for which system at which point in time, and whether the organism may first need to be prepared for that stimulus.

Contact: marion@massafra-schneider.de

Next: Long COVID, Fatigue, and Intermittent Hypoxia

Long COVID may be one of the clearest examples of why diagnosis and regulatory state should never be treated as the same thing.

Why can some people after COVID process carefully dosed physiological challenges well, while others experience delayed symptom exacerbation after even minor exertion? What roles do autonomic dysfunction, exercise intolerance, and PEM or PESE play? And what do we actually know today about the use of IHHT in this patient population?

That is what we will examine much more closely in the next part of this series.

And after that, we will take the next step and become very practical:

How should IHT or IHHT actually be individualized in practice? How do we begin? Which responses should we monitor? When can the stimulus be increased — and when is less, biologically speaking, truly more?

Marion Massafra-Schneider

References and Further Reading

1. Navarrete-Opazo A, Mitchell GS. Therapeutic potential of intermittent hypoxia: a matter of dose. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2014;307:R1181–R1197. This foundational review demonstrates how strongly the effects of intermittent hypoxia depend on the severity, number, duration, and pattern of hypoxic episodes.

2. Doehner W, Fischer A, Alimi B, et al. Intermittent Hypoxic-Hyperoxic Training During Inpatient Rehabilitation Improves Exercise Capacity and Functional Outcome in Patients With Long Covid: Results of a Controlled Clinical Pilot Trial. Journal of Cachexia, Sarcopenia and Muscle. 2024;15(6):2781–2791. A controlled clinical pilot trial investigating IHHT as an adjunct to inpatient multidisciplinary rehabilitation in patients with Long COVID.

3. Marques KC, et al. Reduction of Cardiac Autonomic Modulation and Increased Sympathetic Activity in Long COVID. 2022. This study describes alterations in cardiac autonomic modulation in a cohort of patients with Long COVID.

4. Twomey R, et al. Chronic Fatigue and Postexertional Malaise in People Living With Long COVID. Physical Therapy. 2022. Chronic fatigue and post-exertional symptom exacerbation were common in the cohort studied, highlighting the clinical heterogeneity of Long COVID.

5. Stussman B, et al. Post-exertional malaise in Long COVID. 2025. This study also illustrates why PEM requires careful assessment: self-reported PEM was common, while objectively observed PEM following a standardized exercise challenge was less frequent in the smaller exercise cohort.

6. Zhang Q, et al. Intermittent Hypoxia Conditioning: A Potential Multi-Organ Protective Therapeutic Strategy. 2023. A review of the potential adaptive effects of controlled intermittent hypoxia and the central importance of dose and exposure pattern.

Scientific Note

The evidence regarding intermittent hypoxia — and therapeutic IHHT in particular — remains heterogeneous and is highly dependent on protocol, population, and indication. Findings from sports physiology, healthy populations, experimental hypoxia research, or individual clinical populations cannot automatically be extrapolated to other patient groups.

This is precisely why an individual’s physiological response should not be viewed only as the outcome of an intervention.

It is part of the dosing process itself.